AstraZeneca COVID-19 vaccine shows encouraging phase II results in peer-reviewed study

Data on the final stage of clinical trials is expected soon

AstraZeneca - AstraZeneca COVID-19 vaccine shows encouraging phase II results in peer-reviewed study

The COVID-19 vaccine developed by Oxford University and AstraZeneca PLC (LON:AZN) provokes a strong immune response in the over-60s, according to a study in the Lancet.

Researchers analysed the results of the phase II of clinical trials, which were conducted on 560 healthy adults.

READ: AstraZeneca to release COVID-19 vaccine data imminently, says Jefferies

The prestigious scientific journal said the findings were “encouraging” because older individuals are at disproportionate risk of severe COVID-19.

The inoculation was found to be safe and well-tolerated.

New data from the critical phase III trial is expected soon, as analysts at Jefferies said on Tuesday after a discussion with the pharma giant’s chief financial officer Marc Dunoyer.

Interim results from the final stage of trials in the UK, Brazil and South Africa should come in “days to weeks”, as management already guided for figures to be released by year-end.

The firm is conducting studies on 30,000 people globally to assess the jab.

Meanwhile, a vaccine developed by China's Sinovac Biotech was found to develop a quick immune response in mid-stage trials on 700 people.

“The report on the AstraZeneca and University of Oxford vaccine was less likely to move the dial as, unlike the other major vaccine updates so far, there was no detail on its efficacy,” said AJ Bell investment director Russ Mould.

In fact, markets were focused on rising infections across Europe while the FTSE 100 firm remained flat at 8,168p.

Quick facts: AstraZeneca

Price: 8000 GBX

Market: LSE
Market Cap: £104.98 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Appreciate Group to seize upon £7bln market and grow their share by...

Ian O’Doherty CEO and Tim Clancy from Appreciate Group (LON:APP) talk to Proactive London about their business leading up to the busy Christmas period which is crucial for the firm. O'Doherty says when business is back to normal, they are in the right position to be able to grow their market...

13 hours, 30 minutes ago

2 min read